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Introduction: Significant racial disparities in survival for renal cell carcinoma (RCC) exist 
between whites and blacks. Differences in access to care and comorbidities are possible 
contributors. To investigate if racial disparities persist when controlling for access to care, 
we analyzed data from a single payer healthcare system. 
 
Methods: As part of a case-control study within the Kaiser Permanente Northern 
California system, pathologic and clinical records were obtained for RCC cases (2,152 
white, 293 black) diagnosed from 1998 to 2008. Patient demographics, comorbidities, 
tumor characteristics, and treatment status were compared between whites and blacks. 
Overall survival and disease specific survival (DSS) were calculated by the Kaplan-Meier 
method. A Cox proportion hazards model was used to estimate the independent 
associations of race, comorbidity, and clinico-pathologic variables with DSS. 
 
Results: Compared to whites, blacks were diagnosed at a younger age (median 62 vs. 66 
years, p<0.001), were more likely to have papillary RCC (15% vs. 5.2%, p<0.001), and 
had similar rates of surgical treatment (78.8% vs. 77.9%, p=0.764).  On multivariate 
analysis, advanced AJCC stage, lack of surgical treatment, larger tumor size, and higher 
grade were predictors of worse DSS. Race was not an independent predictor of survival. 
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Conclusions: Within a single healthcare system, we observed differences in characteristics 
of black and white patients with RCC; black patients had different comorbidities, were 
younger, and had decreased tumor stage.  However, unlike other series, race was not an 
independent predictor of DSS, suggesting that survival differences in large registries may 
result from barriers to healthcare access and/or comorbidity rather than disease biology. 
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INTRODUCTION 
 
Renal cell carcinoma (RCC) is a group of tumors arising from parenchyma of the kidney. 
RCC is the seventh most common malignancy in the United States with approximately 
60,000 new cases and 14,000 deaths estimated for 2016. It accounts for 95% of kidney 
cancers diagnosed in the United States.1 
Rising RCC Incidence over the Last 30 Years 
The incidence of RCC has been increasing in the United States over the last few decades.2-
5
 This trend was first reported in a study published at the end of the last century looking 
at rates of RCC from 1975 to 1995 using population-based data from 10 cancer registries 
that are part of the National Cancer Institute (NCI)’s Surveillance Epidemiology, and End 
Results (SEER) program. Chow et al found that incidence of RCC had increased across 
all racial groups with the greatest increase occurring in localized tumors2. Another study 
using population-based data from 13 cancer registries that are part of the SEER program, 
found that age-adjusted incidence rates of RCC nearly tripled from 6.5/100 000 person-
years in 1975 to 17.1/100 000 person-years to 2009.  More recent data shows the trend of 
rising in incidence has not abated with age-adjusted incidence of RCC increasing annually 
by of 2.80% from 2000 to 2009 which is similar to rate of 2.76% from 1975 to 1999.4 
What is driving this increase in incidence? There is consensus that increased incidental 
detection from an expanding role of diagnostic imaging is a significant contributor.2,4 As 
noted by both SEER-based studies2,4, that time period also saw a concurrent rise in the use 
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of diagnostic imaging6,7. Citing data from Medicare beneficiaries, Chow et al found a 76% 
increase in CT scans or MRI between 1986 and 1994.2 The use of CT scans in Medicare 
patients is estimated to have grown at 8% annually from 1980 to 2006 with abdominal 
imaging growing at an even faster annual rate of 9%.6 Internationally, developed nations 
in Western Europe and America have also seen a rising RCC incidence, now approaching 
double that of less developed regions of the world in Africa and Latin America where 
imaging use is not as prevalent.8 This further bolsters the argument that an association 
exists between increased use of cross-sectional imaging and the amount of RCC 
diagnosed. 
However, rising incidental detection from expanding use of imaging studies may not 
explain all of the increase in recent decades. Expectedly, the detection of small, localized 
tumors increased with more frequent imaging, but locally advanced and metastatic tumors 
have also consistently risen in the interval period considered2,4. This suggests that while 
increased use of imaging modalities may have contributed to increased incidental 
detection, it does not wholly explain it. Increases in prevalence of RCC risk factors might 
be a contributor to these trends. 
RCC Risk Factors 
Known epidemiologic risk factors predisposing for RCC including smoking, male 
gender, chronic kidney disease (CKD), hypertension, and obesity9-15. Some of these risk 
factors differ among racial group and may be contributing to the differences in 
epidemiological trends.14,16 Hypertension and chronic kidney disease are two well 
established risk factors that have racial disparity in both prevalence and possibly how 
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they influence RCC. In general, both are more common in blacks. Hypertension has 
been shown to increase the risk of RCC in blacks more than whites, with the greatest 
risk occurring in those with uncontrolled hypertension11. CKD has similarly been shown 
to have a disparate racial influence on RCC with the association being stronger among 
blacks than other racial groups16. 
Obesity rates have been increasing in the US over the last three decades with 35.0% of 
men and 40.4% of women now considered obese. Rates for black males and females are 
higher at 38% and 57.2% respectively.17 High body-mass index (BMI) is an established 
risk factor for RCC.18,19 A meta-analysis of 21 cohort studies with a combined study 
participants of over 9 million and over 15,000 RCC cases across three continents found 
a dose-dependent relationship between BMI and RCC. Risk for RCC increased by 4% 
increased for every 1kg/m2 increase in BMI. 
Epidemiological RCC Trends in Blacks 
In the United States, an emerging body of studies suggests there are some trends peculiar 
to black patients diagnosed with RCC. Significantly, black patients tend to be diagnosed 
at a younger age, have a faster rising incidence rate, are disproportionately diagnosed with 
papillary RCC subtype, overall have more favorable tumor pathology at diagnosis and 
appear to have worse survival outcomes.20-23 
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Incidence of RCC in blacks rising faster than rest of the population 
The increased incidence of RCC in the United States has not been uniform across racial 
groups. RCC has increased faster in blacks than among non-blacks.   Chow’s SEER based 
data showed that over a 20 year period from 1975 to 1995, RCC incidence grew annually 
by 3.9% among black men compared to 2.3% among white men, and 4.3% in black 
women compared 3.1% among white women.2 Reasons for this growth disparity are 
unclear with disparate racial prevalence of risk factors such as obesity, chronic kidney 
disease (CKD) being possible contributing factors16. 
Blacks have more papillary RCC 
The distribution of histologic RCC subtypes is well-characterized with clear cell 
accounting for 70-80% and papillary RCC accounting for 15-20%.24,25 However, recent 
data suggests that black patients diagnosed with RCC disproportionately present with the 
papillary subtype when compared to other racial groups in the US. There is evidence that 
papillary subtype has more favorable outcomes in the general population26-28. This trend 
among blacks was first noted in large-scale population wide studies published within the 
last decade. In a study of nearly 40,000 patients from national cancer registries, blacks 
were diagnosed with papillary RCC at nearly three times the rates of whites (12.5% vs 
4.3%). In a larger study using of nearly 50,000 patients from 18 population-based SEER 
registries across the country, blacks were four times more likely to have the papillary RCC 
subtype than whites.29 It should be noted that these large studies do not included 
pathologic review, although Shuch et al showed that SEER pathologic diagnosis are 
mostly accurate.30  
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Recent studies from single-center academic medical institutions reports similar findings. 
In a study of 1532 patients  (1403 whites, 129 white) done at Vanderbilt University 
Medical Center with a staff surgical pathologist reviewing and confirming the diagnosis, 
blacks were diagnosed with papillary RCC at nearly 3 times the rates of white (35.7% vs 
13.8% ). Conversely, clear cell subtype was only diagnosed in 39.5% of blacks compared 
to 75.9% of whites.20 In a similar study another done at Duke, another tertiary academic 
medical center, looking at 1467 patients (359 blacks, and 1108 non-blacks)  who 
underwent surgical resection for RCC, black patients were diagnosed with papillary RCC 
at almost greater nearly  4 times the rates (40.8% vs 11.6%)21.  
Blacks are diagnosed younger and at an earlier stage 
The median age of kidney cancer is approximately 64 years of age with a fairly wide age 
distribution. Black patients are diagnosed at a younger age compared to white patients. 
In the SEER-based study referenced earlier, 66.7% of RCC diagnosed in blacks were in 
patients younger than 65 years old compared to only 56.7% of whites.9 In a study of 
nearly 40, 000 patients from state of California’s cancer registry from 1988 to 2004, the 
median age for black patients at diagnosis was a 5 years less than white patients31. 
Smaller single-institution studies from tertiary academic hospitals across the US have 
also found similar trends20,21. Reasons for this trend have not been clearly elucidated.  
Blacks have more favorable pathology  
Black patients are more likely to have localized tumors, less likely to have regionally 
advanced and distant metastasis. These trends have been consistently present in using 
population-based data sets from across the country and multiple single-institution data in 
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which tumor pathology by race was included. In Chow’s SEER study, 66.7% of RCC in 
black patients were localized compared to 61.9% in white. In another study of over 12,000 
patients from 9 SEER cancer registries, black patients, compared to whites, were more 
likely to have localized RCC localized (72.6% vs 66.9%), less likely to have metastatic 
disease (14.6% vs 15.3%).9 In the single institution cohort studied by Qi and colleagues, 
blacks, compared to non-blacks, had higher proportion of lower staged tumors, T1a (52.2 
vs 42.7), T1b (23.4% vs 20.8%) and lower proportions of higher staged tumors T3 (14.1% 
vs 23.5%). They also had more localized disease (83% vs 71%) and fewer locally 
advanced (11% vs 16%) and metastatic disease (6% vs 13%).21 
Blacks seem to have worse survival outcomes 
Most significantly is the worse survival outcome for blacks patients with RCC noted in 
large population-wide studies. Two studies published within the last decade using 
population-wide databases found that compared to whites, black patients with RCC had 
worse  outcomes.3,22,31 While black patients present at an earlier disease stage, at a 
younger age, and with more favorable pathology, paradoxically, survival appears to be 
worse.3,22 Even when controlling for treatment and various prognostic factors such as 
stage, tumor size, and grade, a disparity in relative survival still persists between blacks 
and whites with kidney cancer.3 
Unfortunately in the US, access to health care significantly differs by race, which may 
largely account for the observed difference in cancer-related outcomes due to treatment 
barriers. Besides possible differences in tumor biology, this could account for the apparent 
worse survival in black patients with RCC. Data from National Cancer Institute’s 
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Surveillance Epidemiology and End Results (SEER) program demonstrates that blacks 
are less likely to undergo definitive surgical therapy (nephrectomy) 22,32,33. The decreased 
rate of nephrectomy may be influenced by greater pre-existing comorbidities in blacks22. 
However, even when controlling for treatment, other studies have found blacks have 
worse outcome3. 
Analyses of survival outcomes using large registries may be unable to account for barriers 
to care and lead to an improper conclusion that those survival disparities are related to 
tumor biology. Studies have shown that differences in cancer-related outcomes may 
disappear when evaluated in single health care system34,35. By using a single health care 
payer database, we evaluate whether racial survival differences exist while controlling for 
demographics, tumor characteristics, comorbidities, and treatment in a system where all 
patients should receive equivalent care.  
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STATEMENT OF PURPOSE  
 
The goal of this study is to comprehensively assess epidemiologic, clinical, pathological 
and survival outcomes between black and white patients diagnosed with RCC who 
received care within an integrated single-payer health care system.  
Hypothesis 1: We theorized that racial disparity in survival noted between black and 
white patients in population based studies may largely be explained away by barriers 
and/or access to care. These disparity would decrease or disappear when survival 
analyses are performed for a cohort with equivalent access to and quality of care as may 
be found in an integrated single healthcare system.  
Specifically, we tested the hypothesis that there will be no difference in disease specific 
survival outcomes between black and white patients with RCC treated within that system. 
Hypothesis 2: Blacks patients with RCC in this cohort of this study will 
disproportionately present with papillary subtype when compared to whites, as has been 
similarly showing in other datasets.  
Hypothesis 3. We hypothesize that compared to whites, clinico-pathologic (blacks 
diagnosed at a younger age and with more favorable pathology) of black patients will be 
in concordance with previously noted trends found in multiple nationwide datasets
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MATERIALS AND METHODS 
 
Study Design 
 To evaluate racial disparities between whites and blacks in an integrated-managed care 
system, we conducted an investigation among RCC cases from a nested case-control study 
in the Kaiser Permanente Northern California (KPNC) health system16. Patients receiving 
care from KPNC were included in our study if they had been diagnosed with RCC 
(International Classification of Diseases for Oncology, 3rd Edition, site code C64.9) 
between 1998 and 2008. The demographic data were obtained from membership databases 
which include age, race/ethnicity (self-described) and gender.  
The cancer data were obtained from Kaiser Permanente Cancer Registry, which reports 
directly to the Surveillance, Epidemiology, and End Results program. Cancer location, 
tumor size, T stage, grade, AJCC stage, histology, treatment data, and survival were 
recorded for the registry using chart review. Comorbidity data (BMI, smoking history, 
hypertension, diabetes, CKD, any medical renal disease, and anemia), were defined using 
international classification of disease (version 9) coding associated with visits. Tumor 
AJCC stage was re-coded in accordance with current 7th edition guidelines36. Vital status 
and the last follow-up date was available until December 31, 2013. The cause and date of 
death were assigned using a combination of cancer registry data and a mortality registry 
that concatenates state and federal mortality files including primary cause of death from 
California death certifications.  
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Statistical Analysis 
All analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, NC) and R version 
3.1.2 (R Foundation for Statistical Computing, Vienna, Austria). For patient clinical 
characteristics, continuous variables are presented as median (range) and categorical ones 
as frequency with relative percentage. Group comparisons between blacks and whites were 
performed with the use of Fisher’s exact test or chi-square tests for categorical variables 
and Mann–Whitney U tests for continuous variables, as appropriate.  
Overall survival (OS) was measured from the date of diagnosis to the date of death (based 
on the death certificate), alive patients are censored at the date of last follow-up 
date.  Disease-specific survival (DSS) was measured from the date of diagnosis to the date 
of death caused by disease; both alive patients and patients who died due to other causes 
are censored at the last follow-up date and death date respectively. The association of 
survival with clinical and prognostic factors was tested using the log-rank test. Prognostic 
factors that were significantly associated with DSS survival on univariate analysis and 
clinically relevant factors were included in a Cox proportional-hazards model for 
multivariate analysis. Statistical significance was considered for p values ≤ 0.05. 
 
My involvement 
Under supervision of Dr. Shuch, I formulated the research questions and study design. I 
cleaned up the preliminary data file received by removing extraneous information, 
recoding variables as needed, distilling out pertinent data and optimizing dataset for 
statistical analysis. Using the current AJCC 7th edition guidelines and under the direction 
of Dr. Shuch, I went through the entire data and individually determined the appropriate 
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tumor staging. Patients with existing older AJCC staging were updated to the 7th edition. 
AJCC 7th edition staging were deduced from available pathologic data and coded 
accordingly for those with missing entries.  I also did all of the preliminary statistical 
analysis including group comparisons between blacks and whites using the Fisher’s exact 
test or chi-square tests for categorical variables and Mann–Whitney U tests for continuous 
variables, as well as the univariate and multivariate survival analysis, as appropriate.  Final 
statistical analysis presented in the published manuscript and this thesis were done in 
conjunction with Yale Center for Analytical Sciences (YCAS)
12 
 
RESULTS 
 
Patient and Disease Characteristics 
A total of 2,445 patients were included in this study, of which 2,152 (88.0%) were white 
and 293 (12.0%) were black. The clinical and pathological features for entire cohort are 
shown in Table 1. The median age of diagnosis for blacks was significantly lower than for 
whites (62 vs 66 years, respectively, p<0.001) (Table 1). Compared to whites, a higher 
proportion of black patients had a history of hypertension (64.9% vs 50.1%, p<0.001), 
chronic kidney disease (10.2% vs 0.7%, p = <0.001) and anemia (10.2% vs 0.7%, p = 
<0.001). There were no significant racial differences in BMI, diabetes, or smoking history.  
Tumor characteristics significantly differed between whites and blacks. Papillary histology 
was more frequently diagnosed in blacks than in whites (15.0% vs 5.1%, p = <0.001). At 
diagnosis, black patients presented less frequently with metastasis (15.7% vs 22.1%, p = 
0.012) and had a greater frequency of localized disease (AJCC stage I/II) (70.2% vs 62.2%, 
p = 0.008). Although, not reaching statistical significance, blacks tended to have smaller 
sized tumors (4.4 cm vs 5.1 cm, p = 0.066). No racial differences were observed in tumor 
grade and nodal status. No statistical difference was found in the rate of surgical treatment 
between whites and blacks (77.9% vs. 78.8%, p = 0.764).  
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Table 1: Demographic, clinical, pathologic, outcomes data of white and black patients with RCC who 
received care with Kaiser Permanente Northern California from 1998–2008 
 
Variable Blacks (N=293) Whites (N=2152) p value 
Age at diagnosis (years)   <.001 
Median 62 66  
Gender   0.007 
Male 166 (56.7%) 1392 (64.7%)  
Female 127 (43.3%) 760 (35.3%)  
BMI*   0.553 
< 25 9 (15%) 95 (20.8%)  
25  to 30 24 (40%) 163 (35.7%)  
> 30 27 (45%) 199 (43.5%)  
Smoking History   0.263 
Yes 81 (27.65%) 530 (24.6%)  
No 212 (72.4%) 1622 (75.4%)  
Hypertension   <0.001 
Yes 190 (64.9%) 1077 (50.1%)  
No 103 (35.2%) 1075 (49.9%)  
Diabetes   0.094 
Yes 58 (19.8%) 343 (15.9%)  
No 235 (80.2%) 1809 (84.1%)  
CKD   <0.001 
Yes 30 (10.2%) 15 (0.7%)  
No 263 (89.8%) 2137 (99.3%)  
Renal Disease   <0.001 
Yes 35 (11.9%) 49 (2.3%)  
No 258 (88.1%) 2103 (97.7%)  
Anemia   <0.001 
Yes 52 (17.7%) 181 (8.4%)  
No 241 (82.3%) 1971 (91.6%)  
Tumor size   0.066 
Median 4.4 5.1  
Histologic subtype   <0.001 
Clear cell 208 (71.0%) 1829 (85.0%)  
Papillary 44 (15.0%) 111 (5.2%)  
Chromophobe 12 (4.1%) 56 (2.6%)  
Others 29(9.9%) 156 (7.3%)  
Tumor Grade (850 missing)   0.463 
Grade 1 30 (15.2%) 198 (14.2%)  
Grade 2 98 (49.7%) 648 (46.4)  
Grade 3 59 (29.9%) 441 (31.5%)  
Grade 4 10 (5.1%) 111 (7.9%)  
T Stage (193 missing)   0.053 
T1/T2 215 (77.6%) 1424 (72.1%)  
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T3/T4 62 (22.4%) 551 (27.9%)  
N Stage (1 missing)   0.640 
N0/Nx 284 (96.9%) 2095 (97.4%)  
N+ 9 (3.1%) 56 (2.6%)  
M Stage   0.012 
M0/Mx 247 (84.3%) 1677 (77.9%)  
M+ 46 (15.7%) 475 (22.1%)  
AJCC Staging (15 missing)   0.008 
Stage I/II 205 (70.2%) 1330 (62.2%)  
Stage III/IV 87 (29.8%) 808 (37.8%)  
Treatment Option   0.723 
Surgery 231 (78.8%) 1677 (77.9%)  
No surgery 62 (21.2%) 475 (22.1%)  
Vital Status   0.202 
Alive 152 (51.9%) 1031 (47.9%)  
Dead 141 (48.1%) 1121 (52.1%)  
Death from RCC   0.033 
Alive 152 (51.9%) 1031 (47.9%)  
Dead from other cause 64 (21.8%) 626 (29.1%)  
Dead from RCC 77 (26.3%) 495 (23.0%)  
* BMI data only available for patients enrolled from 2005 - 2008 
 
 
 
In patients with clear cell subtype, black patients were diagnosed at a younger median age 
(63 vs. 66, p = 0.003). Blacks with clear cell RCC were less likely to be male (54.3% vs 
63.8%, p = 0.008) (Table 2). Compared to whites, black patients with clear cell RCC were 
also more likely to have been diagnosed with hypertension (64.4% vs 49.9%, p < 0.001), 
over ten times more likely to have been diagnosed with chronic kidney disease (9.6% vs 
0.7%, p < 0.001), and twice as likely to have had anemia (16.3% vs 8.4%, p < 0.001) 
(Table 2) There was no statistical difference between blacks and whites with clear cell RCC 
in tumor grade, size, nodal, or metastatic status. There was also no statistical difference 
between blacks and whites in the percentage of patients that underwent surgery (71.6% vs 
76.0%, p = 0.173) (Table 2) 
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Table 2: Demographic, clinical, pathologic, outcomes data of white and black patients with clear cell RCC 
and received care with Northern California Kaiser Permanente General from 1998–2008 
 
Subcategory Blacks ccRCC Whites ccRCC p value 
 N=208 N=1829  
Age   0.003 
Median 63 66  
Gender   0.008 
Male 113 (54.3%) 1166 (63.8%)  
Female 95 (45.7%) 663 (36.2%)  
BMI*   0.824 
< 25 6 (16.2%) 75 (19.7%)  
25 to 30 15 (40.5%) 138 (36.2%)  
>30 16 (43.2%) 168 (44.1%)  
Smoking History   0.610 
Yes 54 (26.0%) 445 (24.3%)  
No 154 (74.0%) 1384 (75.7%)  
Hypertension   <0.001 
Yes 134 (64.4%) 913 (49.9%)  
No 74 (34.6%) 916 (50.1%)  
Diabetes   0.072 
Yes 45 (21.6%) 305 (16.7%)  
No 163 (78.4%) 1524 (83.3%)  
CKD   <0.001 
Yes 20 (9.6%) 12 (0.7%)  
No 188 (90.4%) 1817 (99.3%)  
Any renal disease   <0.001 
Yes 22 (10.6%) 42 (2.3%)  
No 186 (89.4%) 1787 (97.7%)  
Anemia   <0.001 
Yes 34 (16.3%) 153 (8.4%)  
No 174 (83.7%) 1676 (91.6%)  
Tumor size (cm)   0.118 
Median 4.0 5.1  
Tumor Grade   0.396 
Grade 1 19 (14.7%) 174 (14.7%)  
Grade 2 71 (54.2%) 558 (47.2%)  
Grade 3 35 (26.7%) 365 (30.9%)  
Grade 4 6 (4.6%) 84 (7.1%)  
T stage    0.3833 
T1/T2 144 (74.6%) 1197 (71.6%)  
T3/T4 49 (25.4%) 474 (28.4%)  
N Stage   0.882 
N0/Nx 203 (97.6%) 1787 (97.8%)  
N+ 5 (2.4%) 41 (2.2%)  
M Stage   0.445 
M0/Mx 165 (79.3%) 1408 (77.0%)  
M+ 43 (20.7%) 421 (23.0%)  
AJCC Stage   0.347 
Stage I/II 135 (65.2%) 1123 (61.9%)  
Stage III/IV 72 (34.8%) 692 (38.1%)  
Surgery   0.173 
Yes 149 (71.6%) 1390 (76.0%)  
No 59 (28.4%) 439 (24.0%)  
* BMI data only available for patients enrolled from 2005 - 2008 
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In comparing black and white patients diagnosed with papillary RCC, the median age at 
diagnosis for black patients was also younger (57.5 vs 64, p = 0.003) with the racial age 
gap being larger than clear cell RCC. Although not reaching statistical significance, tumor 
size in black patients with papillary renal tumors were larger than white patients (5.35 cm 
vs 4.2 cm, p = 0.063) (Table 3).   
 
Table 3: Demographic, clinical, pathologic, outcomes data of white and black patients with papillary RCC 
and received care with Northern California Kaiser Permanente General from 1998–2008 
 
Subcategory Blacks papRCC Whites papRCC p value 
 N=44 N=101  
Age   0.003 
Median 57.5 64  
Gender   0.528 
Male 32 (72.7%) 87 (78.4%)  
Female 12 (27.3%) 24 (21.6%)  
BMI*   0.188 
< 25 2 (11.1%) 12 (28.6%)  
25 to 30 7 (38.9%) 18 (42.9%)  
>30 9 (50%) 12 (28.6%)  
Smoking History   0.272 
Yes 20 (45.45%) 39 (35.1%)  
No 24 (54.55%) 72 (64.9%)  
Hypertension   0.095 
Yes 33 (75%) 66 (59.5%)  
No 11 (25%) 45 (40.5%)  
Diabetes   0.595 
Yes 7 (15.9%) 13 (11.7%)  
No 37 (84.1%) 98 (88.3%)  
CKD   0.006 
Yes 7 (15.9%) 3 (2.7%)  
No 37 (84.1%) 108 (97.3%)  
Any renal disease   0.002 
Yes 9 (20.45%) 4 (3.6%)  
No 35 (79.55%) 107 (96.4%)  
Anemia   0.088 
Yes 8 (18.2%) 9 (8.1%)  
No 36 (81.2%) 102 (91.9%)  
Tumor size   0.063 
Median 5.35 4.2  
Tumor Grade   0.311 
Grade 1 7 (21.2%) 12 (15.8%)  
Grade 2 14 (42.4%) 45 (59.2%)  
Grade 3 12 (36.4%) 18 (23.7%)  
Grade 4 0 (0%) 1 (1.3%)  
T stage    1.000 
T1/T2 38 (88.4%) 97 (89%)  
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T3/T4 5 (11.6%) 12 (11%)  
N Stage   0.319 
N0/Nx 42 (95.5%) 109 (98.2%)  
N+ 2 (4.5%) 2 (1.8%)  
M Stage   0.676 
M0/Mx 43 (97.7%) 106 (95.5%)  
M+ 1 (2.3%) 5 (4.5%)  
AJCC Stage   1.000 
Stage I/II 37 (84.1%) 93 (83.8%)  
Stage III/IV 7 (15.9%) 18 (16.2%)  
Surgery   1.000 
Yes 42 (95.5%) 105 (94.6%)  
No 2 (4.5%) 6 (5.4%)  
* BMI data only available for patients enrolled from 2005 - 2008 
 
 
Comparing clinical and demographic data for black patients only, the median age of those 
diagnosed with papillary RCC was 5.5 years less than black patients diagnosed with clear 
cell RCC (57.5 vs 63, p = 0.003). Blacks with papillary RCC were also more likely to be 
male (72.7% vs 54.3%, p = 0.025), and significantly more likely to have a smoking 
history (45.5% vs 26%, p = 0.010) compared to those with clear cell RCC. (Table 4) 
 
 
Table 4: Demographic, clinical data of black patients with papillary RCC and clear cell RCC who received 
care with Northern California Kaiser Permanente General from 1998–2008 
Subcategory Blacks papRCC Blacks ccRCC p value 
 N=44 N=208  
Age   0.003 
Median 57.5 63  
Gender   0.025 
Male 32 (72.7%) 113 (54.3%)  
Female 12 (27.3%) 95 (45.7%)  
BMI*   0.928 
< 25 2 (11.1%) 6 (16.2%)  
25 to 30 7 (38.9%) 15 (40.5%)  
>30 9 (50%) 16 (43.3%)  
Smoking History   0.010 
Yes 20 (45.45%) 54 (26.0%)  
No 24 (54.55%) 154 (74.0%)  
Hypertension   0.178 
Yes 33 (75%) 134 (64.4%)  
No 11 (25%) 74 (35.6%)  
Diabetes   0.394 
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Yes 7 (15.9%) 45 (21.6%)  
No 37 (84.1%) 163 (78.4%)  
CKD   0.280 
Yes 7 (15.9%) 20 (9.6%)  
No 37 (84.1%) 188 (90.4%)  
Any renal disease   0.069 
Yes 9 (20.45%) 22 (10.6%)  
No 35 (79.55%) 186 (89.4%)  
Anemia   0.767 
Yes 8 (18.2%) 34 (16.35%)  
No 36 (81.2%) 174 (83.65%)  
* BMI data only available for patients enrolled from 2005 - 2008 
 
 
 
Survival Analysis 
RCC deaths were more frequent in black patients compared to whites (26.3% vs. 23.0%, p 
= 0.033). Median follow-up time for all black patients was 5.5 years compared to 4.5 years 
for all white patients. Overall, median follow-up time in all the surviving patients was 7.24 
years. In the univariate analysis, there was no significant difference in terms of overall 
survival between black patients and whites (p = 0.21) (Figure 1).  The median OS time for 
blacks is 8.47 years with 95% confidence interval (6.86, 11.75) and the median OS for 
whites is 7.74 years with 95% confidence interval (7.09, 8.43).   
Surprisingly, blacks were found to have improved DSS (p = 0.016) (Figure 2). The five 
and ten-year DSS estimates for blacks vs. whites were 78% and 75% vs 71% and 67%, 
respectively.  
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Figure 1: Overall Survival (OS) for Black and White patients diagnosed with kidney cancer who received 
treatment within Northern California Kaiser Permanente General between 1998 - 2008 
 
 
Figure 2: Disease Specific Survival (DSS) for Black and White patients diagnosed with kidney cancer who 
received treatment within Northern California Kaiser Permanente General between 1998 – 2008 
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In comparing DSS for the two largest histological subtypes, DSS between black and white 
patients with clear-cell appear to be nearly identical (Figure 3) with a 5-year survival of 
72% for black patients versus 70% for white patients.  
 
 
Figure 3: Disease Specific Survival (DSS) for Black and White patients diagnosed with Clear-Cell kidney 
cancer 
 
 
 
 
For papillary RCC, although while statistically not significant, there was a trend for 
improved DSS for black patients with a 5 year survival of 92% versus 78% for whites (p = 
0.084). The survival advantage trends for black patients persisted through 10 years of 
follow up (Figure 4). 
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Figure 4: Disease Specific Survival (DSS) for Black and White patients diagnosed with Papillary kidney 
cancer  
 
 
 
 
 
In univariate analysis, race, age, AJCC stage, grade, tumor size, histology, and receipt of 
surgery were found to be predictors of DSS (Table 5).  AJCC tumor staging was the most 
significant predictor of adverse survival with more advanced stages (AJCC stages 3 and 
4) carrying much more risk than earlier stages (AJCC stage 1& 2 (HR 15.1, p <0.001). 
Higher grades were also predictors of worse outcomes with grade 3 and grade 4 tumors 
carrying 6.92 and 2.92 times the risk of lower grade tumors. (Table 5)  
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Table 5: Univariate analysis of prognostic clinicopathologic variables for Disease Specific Survival (DSS) 
in patients with kidney cancer who received care with Northern California Kaiser Permanente General from 
1998–2008 
 
Variable Hazard Ratio (HR) 95% CI p value 
Age 1.026 1.02–1.03 <0.001 
Gender   0.889 
Male 1.00 (ref)   
Female 0.89 0.85–1.55  
Race   0.016 
White 1.00 (ref)   
Black 0.73 0.57–0.95  
Smoking History 1.01 0.85–1.20 0.914 
Hypertension 1.03 0.89–1.20 0.683 
Diabetes 0.95 0.77–1.17 0.607 
Anemia 0.86 0.65–1.13 0.285 
Renal Disease 0.59 0.34–1.02 0.060 
Tumor size (cm) 1.04 1.04–1.05 <0.001 
Tumor Grade    <0.001 
Grade 1 & 2 1.00 (ref)   
Grade 3 2.92 2.27–3.75 <0.001 
Grade 4 6.92 5.05–9.48  
Histological Subtype   0.364 
Clear Cell 1.00 (ref)  <0.001 
Papillary 0.24 0.14–0.42 <0.001 
Others 0.80 0.61–1.04 0.092 
AJCC Stage   <0.001 
Stage 1 & 2 1.00 (ref)   
Stage 3 & 4 15.5 12.6–18.9  
Treatment Status   <0.001 
Surgery 1.00 (ref)   
No Surgery 12.0 10.3–14.1  
 
 
In multivariate analysis, only larger tumor size, higher tumor grade, advanced AJCC stage 
and not being treated with surgery were found to be independent predictors of DSS. Age, 
histology, and race were no longer associated with DSS (Table 6).  
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Table 6: Multivariate analysis of prognostic variables for Disease Specific Survival (DSS) in patients with 
kidney cancer who received care with Northern California Kaiser Permanente General from 1998–2008 
 
Variable Hazard Ratio (HR) 95% CI p value 
Age 1.001  0.896 
Gender   0.964 
Male 1.00 (ref)   
Female 0.99 0.78–1.27  
Race   0.382 
White 1.00 (ref)   
Black 0.82 0.52–1.29  
Renal Disease 1.43 0.52–3.94 0.481 
Tumor size (cm) 1.05 1.04–1.06 <0.001 
Tumor Grade    <0.001 
Grade 1 & 2 1.00 (ref)   
Grade 3 1.86 1.42–2.43  
Grade 4 3.32 2.36–4.69  
Histological Subtype   0.364 
Clear Cell 1.00 (ref)   
Papillary 0.72 0.35–1.49 0.378 
Others 0.809 0.56–1.15 0.241 
AJCC Stage   <0.001 
Stage 1 & 2 1.00 (ref)   
Stage 3 & 4 8.63 6.48–11.5  
Treatment Status   <0.001 
Surgery 1.00 (ref)   
No Surgery 5.74 4.23–7.81  
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DISCUSSION  
 
Using a large single health care system database, we examined the clinico-pathologic 
characteristics and survival outcomes for black and white patients with renal cell carcinoma 
and found that while clinico-pathological differences exist between black and white 
patients, race was not a predictor of disease specific survival. While black patients in 
univariate analysis appeared to have better disease specific survival, race dropped off as an 
independent predictor in multivariate analysis. Only well-established prognostic variables 
such as tumor size, stage, grade, and surgical treatment influenced outcomes. Despite 
papillary kidney cancer being three times more common in blacks and a more indolent 
RCC variant, histology did not appear to influence prognosis. Paradoxically, we noted that 
DSS was significantly improved in black patients prior to adjusting for other prognostic 
variables. This finding is likely driven by the racial differences observed in epidemiologic 
and tumor characteristics in black patients including more favorable age at diagnosis, tumor 
stage, lower incidence of metastatic disease, and smaller tumors.  
The lack of a racial survival disparity observed in our study contrasts sharply with several 
previous studies using large population-wide databases that consistently demonstrated 
worse survival outcomes for blacks with RCC3,22,31. Specifically, in a study of nearly 
40,000 patients Chow et al found that black patients were at a survival disadvantage to 
white patients that could not be explained by era of diagnosis, histological subtype, size 
and stage of tumors3. Their results are consistent with other population-wide RCC survival 
studies published within the last decade. Whereas Chow et al looked at nationwide data, 
Stafford et al using statewide data from California Cancer Registry examined survival 
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outcomes in 39,434 cases diagnosed with RCC between 1998 and 200431. Their studies 
included other racial groups in addition to whites and blacks. Their findings yet were 
similar. In a study comparing Asian/pacific Islanders, Hispanics, white and blacks, relative 
survival was found to be the worse for blacks than non-blacks. This was true despite black 
patients having a relatively greater percentage of localized RCC. This disparity persisted 
at up to 10 years of follow-up. In our study, black patients with RCC underwent surgical 
therapy at similar rates to white patients. Rates of surgical intervention was not available 
for both the Chow et al and Stafford et al studies although another study suggest blacks 
may be undergoing surgeries at lower rates than whites22. 
Survival results from our study are consistent with findings from a recently published study 
who similarly found no racial disparities in overall survival for RCC patients treated within 
the same health care system. Lin et al evaluated a similar sized cohort of RCC patients 
(2056 white and 370 black patients) treated at military treatment facilities within the 
Department of Defense’s (DOD) health care system and found no differences in overall 
survival by race after adjustment for demographic, tumor and treatment factors.35 
This consistency with our findings is noteworthy given the differences between our study 
population and that of Lin et al, which only included active-duty military personnel, 
retirees, and dependents. Despite the DOD health care system eliminating many barriers to 
access to care, patients frequently have supplemental health insurance and may receive 
some medical services outside the military system. Lin and colleagues also evaluated only 
overall survival while we focused on DSS, a much more important measure of biologic 
aggressiveness. In a population with significant differences in age and comorbidity, an 
analysis of overall survival alone may mask potential racial differences in disease biology 
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that can influence prognosis. Lin et al study only included patients with clear-cell RCC. 
Other subtypes were excluded on grounds of insufficient numbers. Given that papillary 
subtype is significantly more common in black patients, we believe that our approach of 
including all subtypes, particularly papillary subtype, provides a more complete 
assessment. 
 While our study and Lin’s did not demonstrate a racial disparity in survival among black 
patients with RCC, we must acknowledge that our cohort, despite equivalent access to care, 
is rather homogenous in many respects to the subjects in the other studies. The larger 
population-based studies probably better reflect the US population as a whole. It is widely 
known racial disparities exist in employment, health coverage, and socioeconomic status. 
All black patients in this cohort likely received their healthcare coverage through their 
employer or their spouse’s, making them more likely to be in a higher socioeconomic 
group. We recognize that these factors may affect treatment availability and options, which 
were not accounted for in our studies. It is possible that blacks in our study cohort, 
compared to blacks in the general population, have better access to care and are therefore 
being diagnosed earlier contributing to the more favorable outcomes noted in this study. 
Socioeconomic differences may largely explain disparities in cancer stage observed among 
black patients with various forms of malignancy37,38. Within RCC, lower socioeconomic 
status has similarly demonstrated an association with advanced tumor stage39. Not 
surprisingly, socio-economic status significantly influences survival for a wide variety of 
cancers40.  
Despite evaluating patients within a single health care system, among individuals with 
kidney cancer, there were significant racial differences in both patient and tumor 
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characteristics. The age at diagnosis of kidney cancer was significantly younger in blacks 
similar to other both national and multiple single-institution cohorts.21,22,31,35. 
We found that papillary RCC was nearly threefold more common in black patients 
compared to white patients in our cohort. This is consistent with prior single institutional 
and national registry cohorts that demonstrate a similar increased frequency of papillary 
histology in black patients29,41. Various factors could account for this finding. Specific risk 
factors for kidney cancer including hypertension, obesity, and chronic kidney disease 
greatly differ by race14,16. Limited studies have evaluated how each of these factors 
influence the risk of specific histologic types of kidney cancer. Genetic differences may 
also contribute to a different distribution of histologic subtype. Recently, genome wide 
association studies (GWAS) have been performed in different racial groups. Interestingly, 
specific kidney cancer susceptibility loci may differ in the black population 42. Recently, 
black patients with clear cell RCC were shown to overexpress BAP1 relative to whites43. 
BAP1 overexpression is associated with more favorable pathological staging, conversely 
its silencing portends worse outcomes. Future case–control studies evaluating kidney 
cancer susceptibility should focus on specific histologic subtypes, as the genomic basis of 
each differs greatly44. 
The presence of comorbidities with known racial differences such as CKD and 
hypertension were significantly increased in blacks with kidney cancer. Both of these 
factors have been shown to increase kidney cancer risk and could explain some of the 
recent epidemiologic trends in kidney cancer incidence in blacks14-16. Additionally there 
could be a detection bias in blacks, as often patients with an unknown cause of CKD 
undergo renal imaging to determine etiology. This practice could lead to increased 
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incidental detection and skew presentation towards earlier stage disease, resulting in lead-
time bias.  With equal access to health care in the Kaiser System and potential early 
detection of CKD, racial differences in the stage of RCC perhaps may be even more 
pronounced than observed in other healthcare systems. 
In this study, we found that unfavorable tumor histological and clinical features portend 
worse outcomes. We found AJCC staging to be the most powerful independent predictor 
of outcomes. In our multivariate analysis, patients presenting with higher AJCC stages 
(stages 3 and 4) carried eight times risk of disease specific mortality compared to those 
presenting with AJCC stages 1 and 2. This result is not unexpected given that AJCC staging 
is a measure of anatomical tumor extent and a well-established prognosticator of outcomes 
45
. AJCC stage 3 are tumors that that are either large in size, or of any size that but extending 
into major veins, may have spread to nearby lymph nodes but overall still confined within 
Gerota’s fascia. AJCC stage 4 tumors are tumors that have grown beyond Gerota’s fascia, 
distant node involvement or metastasis.  
Independent of AJCC staging, we also found tumor size to be a predictor of worse disease 
specific outcomes with each additional centimeter in tumor length conferring 5% increase 
in risk. Risk of malignancy and higher tumor grades has been shown to increase with tumor 
size in renal masses without diagnosis46.  Expectedly, high tumor grades were also 
independent predictors of worse outcomes with grade 3 tumors carrying nearly double the 
risk, and grade 4 tumors carrying over the three times the risk of adverse disease specific 
outcomes. While male gender is a known risk factor for RCC, we found no evidence that 
gender was a significant prognosticator of outcome.  
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Our study also showed that not having surgery was a significant independent 
prognosticator of worse outcomes with patients who did not undergo surgery had nearly 
six times the risk of disease-specific mortality. We believe that most of the subjects not 
undergoing surgery are either patients with metastatic tumors that are not amenable to 
surgical treatment or people with serious comorbidities precluding them from undergoing 
surgery. Both of those categories of patients inherently carry a higher risk of mortality and 
may largely explain the vastly inferior survival associated with not having surgery.  
Histologically, we found that while on univariate analysis papillary RCC subtype seems to 
have better outcomes compared to clear cell, histological subtype was not found to be an 
independent predictor of outcomes. There have been studies showing similar findings of 
trends towards better outcomes with papillary subtype27,28. We did not have sufficient data 
to evaluate other subtypes might influence overall outcomes  
To the best of our knowledge, this is the first study examining disease‐specific survival 
disparities in individuals with kidney cancer treated within a single regional healthcare 
system. We recognize that participation in such a healthcare system does not guarantee 
equal treatment; however, it can minimize disparate racial access. A strength of our study 
is that our data displays the added advantage of having cancer‐specific outcomes especially 
since other common causes of mortality, including cardiovascular disease, also have racial 
disparities47,48. Unlike studies based only on cancer registry data, we included comorbidity 
data such as CKD. Inclusion of this may be critical to survival analyses as a recent paper 
suggests renal comorbidities account for much of the observed racial disparity37. Besides 
influencing overall survival, comorbidities may influence specific treatment decisions and 
similarly affect cancer outcome. Information on systemic therapy was not available at time 
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of recurrence; however, the equivalent rates of surgical treatment may serve as a surrogate 
of similar treatment at other stages of disease. 
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CONCLUSION 
 
We found that within a large single healthcare system, while some patient and tumor 
characteristics differed between black and white patients with RCC, surgical treatment 
rates were similar and race was not an independent predictor of disease‐specific survival. 
Our studies suggest that the disparities in kidney cancer survival outcomes between black 
and white patients noted in national registries likely result from barriers to access to care 
rather than disease biology. Future work should focus on identifying, understanding, and 
then eliminating possible racial barriers to kidney cancer treatment in other healthcare 
systems. 
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